Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.
As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
2d
A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top ...
In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback